22:58 , Apr 4, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
14:29 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

Pan-ALDH1A inhibitor for ovarian cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer In vitro , cell culture and mouse studies identified a pan-ALDH1A inhibitor that could help treat ovarian cancer. Chemical synthesis and in vitro testing of diethylaminobenzaldehyde analogs yielded a...
22:59 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest the generic antibiotic nifuroxazide could help treat melanoma. In two human metastatic melanoma cell lines, nifuroxazide plus the BRAF inhibitor Zelboraf vemurafenib and the MEK inhibitor Mekinist...
22:06 , Apr 28, 2017 |  BioCentury  |  Emerging Company Profile

Cutting cravings

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...
19:49 , Feb 17, 2017 |  BC Week In Review  |  Company News

Gilead, Amygdala deal

Amygdala acquired GS-6637 from Gilead. Gilead received an equity stake and is eligible for undisclosed milestones and royalties. Amygdala expects to begin two or three Phase II trials this year of GS-6637 in alcohol and...
21:05 , Feb 16, 2017 |  BC Extra  |  Company News

Amygdala acquires addiction candidate from Gilead

Amygdala Neurosciences Inc. (Palo Alto, Calif.) said it acquired GS-6637 from Gilead Sciences Inc. (NASDAQ:GILD). The company expects to begin clinical trials this year of the candidate to treat cocaine and alcohol use disorders. GS-6637...
17:40 , Nov 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting FOXD1 or ALDH1A3 could help treat glioma. In patients, high tumor expression of FOXD1 or ALDH1A3 was associated with poor survival. In human...
07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-30a (miR-30a)

Autoimmune disease INDICATION: Multiple sclerosis (MS) Mouse studies suggest promoting miR-30a expression with disulfiram or diphenhydramine hydrochloride could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, IV injection of a...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1); cytochrome P450 26A1 (CYP26A1; CP26)

Cancer INDICATION: Colorectal cancer Patient sample and mouse studies suggest enhancing all-trans retinoic acid (ATRA) levels could help treat colorectal cancer. In tumor samples from colorectal cancer patients, levels of ALDH1A1 - which participates in...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: HCV NS5A protein

Infectious disease INDICATION: Hepatitis C virus (HCV) Cell studies suggest disulfiram could help treat HCV by preventing Zn2+-dependent activity of HCV NS5A. In an in vitro assay, disulfiram displaced Zn2+ from HCV NS5A. In a...